Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.

Grade Last Price % Change Price Change
C 18.55 -3.03% -0.58
ACAD closed down 3.03 percent on Friday, February 7, 2025, on 44 percent of normal volume.
Earnings due: Feb 25
*** please verify all earnings dates ***
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down

Date Alert Name Type % Chg
Slingshot Bullish Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength -3.03%
Overbought Stochastic Strength -3.03%
Upper Bollinger Band Touch Strength -3.03%
Stochastic Reached Overbought Strength -5.36%
Above Upper BB Strength -5.36%
Gapped Up Strength -5.36%
Overbought Stochastic Strength -5.36%
Upper Bollinger Band Touch Strength -5.36%
NR7 Range Contraction -0.96%

   Recent Intraday Alerts

Alert Time
Down 3% about 13 hours ago
Fell Below 10 DMA about 14 hours ago
10 DMA Support about 16 hours ago
Down 2 % about 16 hours ago
Down 1% about 17 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

ACADIA Pharmaceuticals Inc. Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Medication Alzheimer's Disease Chemical Compounds Parkinson's Disease Chronic Pain Neurological Disorders Schizophrenia Central Nervous System Disorders Glaucoma Nervous System Disorders Treatment Of Parkinson's Disease Urological Disorders Treatment Of Glaucoma Treatment Of Chronic Pain Treatment Of Schizophrenia Psychosis

Is ACAD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Comments

Indicators

Indicator Value
52 Week High 26.78
52 Week Low 14.15
Average Volume 2,616,359
200-Day Moving Average 16.46
50-Day Moving Average 17.65
20-Day Moving Average 18.25
10-Day Moving Average 18.69
Average True Range 0.71
RSI (14) 53.27
ADX 18.27
+DI 25.28
-DI 19.51
Chandelier Exit (Long, 3 ATRs) 17.58
Chandelier Exit (Short, 3 ATRs) 18.73
Upper Bollinger Bands 19.60
Lower Bollinger Band 16.91
Percent B (%b) 0.61
BandWidth 14.73
MACD Line 0.40
MACD Signal Line 0.37
MACD Histogram 0.0321
Fundamentals Value
Market Cap 3.09 Billion
Num Shares 166 Million
EPS 0.78
Price-to-Earnings (P/E) Ratio 23.78
Price-to-Sales 3.15
Price-to-Book 5.07
PEG Ratio -0.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.49
Resistance 3 (R3) 19.58 19.36 19.33
Resistance 2 (R2) 19.36 19.12 19.32 19.28
Resistance 1 (R1) 18.96 18.98 18.85 18.86 19.23
Pivot Point 18.74 18.74 18.68 18.69 18.74
Support 1 (S1) 18.33 18.50 18.22 18.24 17.87
Support 2 (S2) 18.11 18.35 18.07 17.82
Support 3 (S3) 17.71 18.11 17.77
Support 4 (S4) 17.61